FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average	e burden								

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

moducion ±(b).			lieu pursuant to section 10(a) or the securities exchange Act or 133.	+		7			
			or Section 30(h) of the Investment Company Act of 1940	and Ticker or Trading Symbol BIO INC [ANAB] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) Chief Medical Officer t, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line)					
Name and Addre	, ,	erson*	2. Issuer Name and Ticker or Trading Symbol <u>ANAPTYSBIO INC</u> [ANAB]		(Check all applicable)				
Londer Marc	<u>U</u>								
			·						
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year)		,	,			
C/O ANAPTYS	BIO, INC.		12/17/2018		Chief Medical	Officer			
10421 PACIFIC CENTER COURT, SUITE 200		JRT, SUITE 200							
<u> </u>			4. If Amendment, Date of Original Filed (Month/Day/Year)	, , ,					
SAN DIEGO CA 92121		\mathbf{X}	Form filed by One Reporting Person						
	92121			Form filed by More than One Reporting					
			_		Person	an One Reporting			
(City)	(State)	(Zip)							

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 2A. Deemed 5. Amount of 6. Ownership 7. Nature 1. Title of Security (Instr. 3) 2. Transaction Transaction **Execution Date** Securities Form: Direct of Indirect (Month/Day/Year) if any (Month/Day/Year) Code (Instr. Beneficially (D) or Indirect Beneficial 8) Owned Following (I) (Instr. 4) Ownership Reported (Instr. 4) (A) or (D) Transaction(s) (Instr. 3 and 4) Price ν Code Amount Common Stock 12/17/2018 $M^{(1)}$ 152,925 D 8,048 \$0.7 Common Stock 12/17/2018 $M^{(1)}$ 22,000 Α \$6.93 174,925 D S⁽¹⁾ \$65.3612(2) D Common Stock 12/17/2018 12,120 D 162,805 $\varsigma(1)$ Common Stock 12/17/2018 3,185 D \$66.3787(3) 159,620 D **S**⁽¹⁾ Common Stock 12/17/2018 8,002 D \$67.5686(4) 151,618 D 12/17/2018 S⁽¹⁾ \$68.4732(5) 144,877 Common Stock 6,741 D D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8) Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Employee Stock Option (Right to Buy)	\$0.7	12/17/2018		M ⁽¹⁾			8,048	(6)	10/27/2024	Common Stock	8,048	\$0.00	10,060	D	
Employee Stock Option (Right to Buy)	\$6.93	12/17/2018		M ⁽¹⁾			22,000	(7)	08/13/2025	Common Stock	22,000	\$0.00	70,223 ⁽⁸⁾	D	

Explanation of Responses:

- 1. The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- 2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$65.00 to \$65.99 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$66.00 to \$66.92 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$67.02 to \$68.01 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 5. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$68.05 to \$68.73 per share, inclusive. The reporting person undertakes to provide to the issuer, any security polder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price
- 6. The stock option vested and became exercisable as to 25% of the shares subject to the option on October 24, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
- 7. The stock option vested and became exercisable as to 25% of the shares subject to the option on August 13, 2016, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
- 8. In addition to the remaining options to purchase 80,283 shares of common stock as set forth in Table II, the Reporting Person also holds (i) 144,877 shares of common stock held directly; and (ii) additional options to purchase up to an aggregate of 138,000 shares of common stock, which options vest according to their terms.

Remarks:

/s/Eric Loumeau, attorney-in- 12/18/2018

fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.